Navigation Links
CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
Date:1/21/2011

and metastasis," said H. Shep Wild, President and Chief Executive Officer of CureFAKtor Pharmaceuticals.  "CureFAKtor's proprietary FAK technology platform may represent a significant breakthrough in the treatment of most solid tumor cancers in that its unique mechanism of action disrupts the signaling of specific protein to protein binding between FAK and tumors."

CureFAKtor recently received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for CFAK-C4 in combination with gemcitabine for the treatment of pancreatic cancer, a disease with the lowest survival rate of any cancer and limited patient treatment options.

About Focal Adhesion Kinase (FAK)Focal adhesion Kinase (FAK) is substantially over-expressed in many solid tumors. FAK operates by placing itself at the contact points between tumor cells and the extra cellular matrix that surrounds them. Studies by CureFAKtor and others found that in this role, FAK is an important facilitator for signals that cause tumor cells to survive, grow, and produce new blood vessels to sustain growth and travel to distant places within the body where they may establish new tumor sites. It also cocoons the tumor cells to protect them from the body's natural signaling mechanisms that would cause deviant tumor cells to be eliminated. In a similar fashion, FAK protects tumors from chemotherapeutic drugs and radiation, allowing the tumor cells to resist these therapies.  

About CureFAKtor PharmaceuticalsCureFAKtor Pharmaceuticals is a biopharmaceutical company focused on the research and development of Focal Adhesion Kinase therapies to prevent or treat cancer. CureFAKtor's investigational and combination therapy products target pancreatic, breast, colon, melanoma, lung and brain oncology disorders. CureFAKtor research is conducted at the Roswell Park Cancer Institute.  CureFAKtor is planning a Phase I clinical study of CFAK-C4 in combination with gemcitabine chemothera
'/>"/>

SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
2. Amylin Pharmaceuticals to Webcast Year-End Financial Results
3. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
4. Federal Government Obtains Permanent Injunction Against Deltex Pharmaceuticals Inc.
5. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
6. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
7. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
8. Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote
9. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
10. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
11. Reportlinker Adds OTC Pharmaceuticals: Global Industry Almanac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
(Date:7/31/2014)... Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... Insulin Pump, today reported its financial results for the quarter ... second quarter of 2014 to the same period of 2013: ... $5.5 million , t:slim Pump shipments grew 64 percent ... six months ended June 30, 2014 to the same period ...
(Date:7/31/2014)... 31, 2014 Nektar Therapeutics (Nasdaq: NKTR ... ended June 30, 2014. Cash and investments ... as compared to $309.1 million at March 31, 2014."The second ... as we look forward to significant milestones for a number ... and Chief Executive Officer of Nektar. "The first of these ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14
... , THOUSAND OAKS, Calif., Dec. 3 Each year, hundreds ... Europe participate in the Amgen Scholars Program to gain hands-on ... universities. Now, the Amgen Scholars - past, present and ... Scholars Community at www.amgenscholars.com . , "The new ...
... MARQUETTE, Mich., Dec. 3 Pioneer Surgical Technology, Inc., ... awards in the Cervical Spine Care category at the ... Francisco, California in conjunction with the North American Spine ... receiving awards were the NuNec® Cervical Total Disc replacement ...
Cached Medicine Technology:New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 2New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 3Pioneer(R) Surgical Technology, Inc. Receives Prestigious Spine Technology Awards 2
(Date:8/1/2014)... OR (PRWEB) August 01, 2014 In ... called hydrotherapy – was fundamental to the practice of ... water researcher Sharon Kleyne, water therapy has been relegated ... time when climate change, water shortages, drought and pollution ... diseases, the Sharon Kleyne Hour Power of Water host ...
(Date:8/1/2014)... According to the Suspension Revolution 2.0 PDF review recently ... and women who want to get ripped abdominals within a ... 27 intense workouts that help blast fat and gain muscle ... Suspension Revolution 2.0 program provides users with easy tips and ... plans that help keep fit and stay healthy ...
(Date:8/1/2014)... August 01, 2014 Blindness is a ... that the scientists of today, despite well-meaning efforts, still have ... a definite treatment for reversing blindness that does not involve ... this is where alternative medicine takes the “slack” from the ... expensive treatments or harmful surgeries. , Alternative health specialist ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Online retailer ... offering a low price guarantee on their inventory of ... adult diapers, wipes, and pads along with other personal ... can be to find a line of incontinence products ... you find one that works for you, you shouldn't ...
(Date:8/1/2014)... York, US (PRWEB) August 01, 2014 ... DataSite in partnership with PitchBook presents the 3Q 2014 ... all U.S private equity investment, exits and fundraising activity ... useful insight to help plan for private equity endeavors ... the registration form to download it now. , About ...
Breaking Medicine News(10 mins):Health News:Water Researcher Advocates Reevaluation of 18th and 19th Century Water Therapy Movement 2Health News:Water Researcher Advocates Reevaluation of 18th and 19th Century Water Therapy Movement 3Health News:Suspension Revolution 2.0 PDF Review Exposes Dan Long's Program For Building Muscle – Vkool.com 2Health News:Suspension Revolution 2.0 PDF Review Exposes Dan Long's Program For Building Muscle – Vkool.com 3Health News:The Miracle Cure Review | The Unbeatable Secret to Reversing Any Vision Problem – Vinamy.com 2Health News:Disposable Medical Express Offering Low Price Guarantee On Tranquility Products 2Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2
... of a recent study researchers say weight gain after age ... for postmenopausal women who // are not taking hormone replacement ... ages 50 to 74, by asking them about their weight ... women have been periodically asked to provide updates on their ...
... in as little as two days of physical inactivity, the ... and other related diseases.// ,Researchers conducted a study in ... stayed inactive. When the rats stopped running for two days ... of sugar taken into the muscle in response to insulin ...
... New research suggests weight loss may be an early ... loss begins before the onset of // definite dementia ... ,Weight loss in the elderly is common and may ... been documented in people who already have dementia. For ...
... surgery may be at higher risk for bone fractures, say ... For the study, nearly 20 percent of men treated with ... diagnosis, compared to about 13 percent of men who did ... given to men with locally advanced cancers and the therapy ...
... estrogen may provide protection against colon cancer. For the ... and followed their progress for one year. The diets were ... one contained milk protein, and diet two had soy protein. ... diets contained soy protein with the addition of an estrogen ...
... genetic discovery could help give insight into a very deadly ... that codes for the progesterone receptor increase a woman’s risk ... to a higher ovarian cancer risk as well as a ... used biological samples from an ongoing study and examined the ...
Cached Medicine News:
The CGPL capsulotomy contact glass was designed by Riquin, Fankhauser et al. for the dissection of opacified posterior lens capsules and membranes in the pupillary and retropupillary space with the Y...
The CGAL gonioscopic contact glass was designed by Roussel and Fankhauser for,laser treatments of the chamber angle. It reduces the laser spot by a factor of 1.5 as compared to a Goldmann Glass....
The CGRL is a Wide Angle Contact Glass designed for laser photocoagulation and diagnosis of the retina....
The classic Goldmann Glass. Designed to work with argon/YAG Lasers....
Medicine Products: